about
Potential therapeutic targets for neurokinin-1 receptor antagonistsA randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adultsInnate immune markers in mothers and fathers of children newly diagnosed with cancer.HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance PSelective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndromeNeurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor.Measurement of plasma-derived substance P: biological, methodological, and statistical considerations.The role of quantitative pharmacology in an academic translational research environmentSubstance P and Human Immunodeficiency Virus Infection: Psychoneuroimmunology.Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor.Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.Neurokinin-1 receptor mRNA expression differences in brains of HIV-infected individualsPharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIVSubstance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophagesExpression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathologyAnalog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS DisordersTachykinins and their receptors: contributions to physiological control and the mechanisms of disease.Substance P and the regulation of inflammation in infections and inflammatory bowel disease.Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis.Substance P-mediated chemokine production promotes monocyte migration.Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.Novel method for determination of substance P levels in unextracted human plasma by using acidification.Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling.Combination ART-Induced Oxidative/Nitrosative Stress, Neurogenic Inflammation and Cardiac Dysfunction in HIV-1 Transgenic (Tg) Rats: Protection by Mg
P2860
Q28262693-1FDB35DD-DF1D-4303-8A4C-122E6B88DDA7Q28740565-D8DEDA19-9555-4EE8-83A3-0A9C5B7DD7C0Q33609448-3CB4B4B4-B52C-411E-BACF-1CBA0C70FED0Q33750864-F2D612D9-38A5-4FC7-AFA5-E8543D982305Q33752757-BF22DE4D-0479-4A7D-899F-F80D9FBA21F1Q34150798-28692D0B-3CEF-43C5-8087-66A87AA51E9BQ34417546-7B201A83-7B99-4447-9E79-103F9AD4253AQ34565970-464E6B5F-D0E0-449D-B506-79208964C19EQ34774991-607B2690-0843-4FFB-9079-A7BD1384EB6AQ35135953-C85423E2-58E9-4605-A0CC-F9C7CBCCD9A4Q35753947-0B5BE6F0-D807-4C02-BB6F-334308746F4CQ35755634-4952B36C-8FB6-465E-8846-9447C8D8B474Q36043712-51D0E059-96F6-4D2D-9A46-76893E50C5F5Q36906584-3C2EC7B4-C0EF-4DCE-BE2A-FA2737F07DA7Q36937565-3744D34F-8877-4362-95C0-54016B59F235Q37034775-98CD701E-3DF3-4130-BA0E-852A189BDA89Q37176010-DCF1BABA-6686-42C7-8FA7-844F48C2FC76Q37302953-A2CC152A-8C07-4641-9AAE-8BD2E68C9F93Q37340453-693E61C0-58EE-4B78-9402-05E8953A4587Q37553389-BD8596FB-A486-45E4-B7E8-39868003BF7FQ37593097-B1E3153C-825F-4CE8-B2D9-EF4B9C0304A1Q38271424-DF594078-FCB8-46DC-BD59-C5208095DC6BQ40085168-1FF4CD58-6519-4D7F-B206-375BF748B3B1Q40268840-8079AD7D-4831-4F73-B693-ADB3436EF113Q41924104-837D6C66-F5BB-49AC-A4B5-E865F93F2DA3Q43146586-D3BA6CBB-FE6F-400E-AB68-EB8B0B69A5C0Q49972918-EA6B8DD7-2309-42A6-8612-4FA635127D9DQ58776477-F10B533E-F921-4A3F-928E-565C537E048A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Elevated substance P levels in HIV-infected men.
@ast
Elevated substance P levels in HIV-infected men.
@en
Elevated substance P levels in HIV-infected men.
@nl
type
label
Elevated substance P levels in HIV-infected men.
@ast
Elevated substance P levels in HIV-infected men.
@en
Elevated substance P levels in HIV-infected men.
@nl
prefLabel
Elevated substance P levels in HIV-infected men.
@ast
Elevated substance P levels in HIV-infected men.
@en
Elevated substance P levels in HIV-infected men.
@nl
P2093
P1433
P1476
Elevated substance P levels in HIV-infected men.
@en
P2093
Douglas SD
Leserman J
Petitto JM
P304
P356
10.1097/00002030-200110190-00019
P407
P577
2001-10-01T00:00:00Z